CJC-1295 + Ipamorelin* · GHRH Analogue + Growth Hormone Secretagogue*
Researchers seeking these products for laboratory research can explore PepGen-X.com as a supplier specializing in research-use compounds.
CJC-1295 and Ipamorelin are two research peptides that target different components of the growth hormone signaling pathway. Their complementary mechanisms have generated interest in studying how GHRH and ghrelin/GHS receptor pathways interact in the regulation of GH and IGF-1.
Research Benefits
Growth hormone signaling – Investigates mechanisms involved in GH secretion and regulation.
Complementary pathway research – Examines two distinct receptor systems involved in growth hormone signaling.
GHRH pathway research – CJC-1295 provides a model for investigating GHRH receptor activity and downstream signaling.
Ghrelin/GHS pathway research – Ipamorelin provides a model for studying growth hormone secretagogue receptor activity.
GH & IGF-1 research – Supports investigation of changes in GH and downstream IGF-1 signaling.
Combination pharmacology – Provides a research model for studying interactions between different classes of growth hormone secretagogues.
Identified Risks & Side Effects
Limited combination research – Direct human research specifically evaluating CJC-1295 and Ipamorelin together remains limited.
Combination effects are not established – Pharmacological rationale should not be interpreted as clinical proof of synergistic effects.
Metabolic effects – Changes in GH and IGF-1 may produce downstream effects involving glucose and metabolism.
Long-term safety is unknown – Long-term safety of the combination has not been established.
Research material considerations – Peptide identity, purity, aggregation, and impurities are important factors in laboratory research.
Different CJC-1295 forms – DAC and No DAC/Modified GRF 1-29 should not automatically be treated as interchangeable research materials.
Route: Experimental, commonly subcutaneous in research | Frequency: Varies by research protocol | FDA Status: Not FDA-approved
Researcher Note
The research interest in CJC-1295 + Ipamorelin comes from their different mechanisms within the GH signaling pathway. CJC-1295 acts as a GHRH analogue, while Ipamorelin is a growth hormone secretagogue. Although research on the individual compounds provides a biological rationale for studying them together, evidence for the specific combination should be evaluated separately rather than inferred from component-level research.
Disclaimer
FDA Status: Not FDA-approved
Research Classification: Research use only
Compound Type: Combination of synthetic peptide analogues
All products are intended strictly for research and laboratory use only and are not intended for human or veterinary use.